Tarsus Pharmaceuticals reports Q4 EPS (60c), consensus (82c)

Reports Q4 revenue $66.4M, consensus $58.8M. “Tarsus’ demonstrated category-creating blueprint has established XDEMVY as one of the most successful eye care launches to date,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “We believe we are only beginning to unlock our full potential as the next leader in eye care and have so much to look forward to, including, potentially serving the millions of patients impacted by Demodex blepharitis, continuing to uncover new therapeutic indications and deepening our impact across eye care.”